Effect of SGLT2 inhibitors on heart failure outcomes in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials. [PDF]
Exp Ther MedBafail DA, Alhalees NH.
europepmc +1 more source
Repurposing SGLT2 Inhibitors for Cirrhotic Ascites: From Mechanistic Research to Clinical Exploration. [PDF]
J Clin Transl HepatolGao Y, Gao Y, Ji D, Hu Z.
europepmc +1 more source
Assessing Renoprotective Effects of Empagliflozin and Telmisartan Combination Therapy in Non-albuminuric Diabetic Nephropathy: A Retrospective Cohort Study. [PDF]
CureusAcharya A +6 more
europepmc +1 more source
Comparison of the Efficacy of Empagliflozin, Dapagliflozin, and Allopurinol Based on Serum Uric Acid Levels and Kidney Function in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study. [PDF]
Med Sci (Basel)Fejes R +3 more
europepmc +1 more source
Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial. [PDF]
Diabetol Metab SyndrMahboub BM +4 more
europepmc +1 more source
Empagliflozin-Induced Liver Injury. [PDF]
Eur J Case Rep Intern MedGonçalves HD +6 more
europepmc +1 more source
Benefits of SGLT2 inhibitors in patients with diabetes and advanced chronic kidney disease - where have we gone so far? [PDF]
Front Clin Diabetes HealthcDuni A +7 more
europepmc +1 more source
Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching. [PDF]
PLoS OneYuan Z +6 more
europepmc +1 more source
Role of Sodium-Glucose Transport Protein-2 Inhibitors in Renal Protection: A Narrative Review from the Cardiovascular-Kidney-Metabolic Interconnection. [PDF]
Drug Des Devel TherYe N, Cheng H.
europepmc +1 more source